文献速递肾癌与肾肿瘤

转移性非透明细胞肾细胞癌的治疗选择与挑战

Management of Metastatic Nonclear Renal Cell Carcinoma: What Are the Options and Challenges?
PubMed 文献 · Eur Urol Oncol · 2020-06-15

本文报道一例68岁女性原发性转移性非透明细胞肾细胞癌(RCC)伴多发骨病变,接受颅骨病灶切除和减瘤性肾切除,病理为嗜酸细胞性乳头状RCC。术后3个月内出现骨进展,一线舒尼替尼治疗第三周期后骨转移进展,二线卡博替尼治疗有应答。非透明细胞RCC缺乏特异性系统治疗,免疫治疗数据有限,强烈推荐患者参加临床试验。

要点

  • 非透明细胞RCC缺乏特异性系统治疗,免疫治疗数据有限。
  • 转移性非透明细胞RCC患者生存较差,应强烈推荐参加临床试验。
  • 本病例二线卡博替尼治疗有应答,但总体治疗选择有限。

核心结论

  • 非透明细胞RCC的主要未满足需求是缺乏特异性系统治疗,免疫治疗数据仍有限。
  • 强烈推荐将转移性非透明细胞RCC患者纳入临床试验。

研究设计与样本

  • 本文为病例报告,描述一例68岁女性原发性转移性非透明细胞RCC伴多发骨病变的诊治过程。

主要发现

  • 患者接受颅骨病灶单次切除(病理为低分化癌,原发不明)和减瘤性肾切除,肾标本病理为嗜酸细胞性乳头状RCC。
  • 术后3个月内出现骨骼进展,开始舒尼替尼治疗,初始稳定后第三周期出现骨转移进展。
  • 二线卡博替尼治疗有应答。

临床怎么用

  • 转移性非透明细胞RCC患者应优先考虑参加临床试验,尤其是免疫治疗联合方案的试验。

局限性

  • 本文为单例病例报告,结论外推受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This case presents a 68-yr-old female patient with primary metastatic nonclear renal cell carcinoma (RCC) with multiple bone lesions. The patient underwent a single resection of skull bone lesion (diagnostic for poorly differentiated carcinoma of unknown origin) and cytoreductive nephrectomy. The pathology of the kidney specimen demonstrated an oncocytic papillary RCC. Within 3 mo, she developed skeletal progressive disease and was started on systemic therapy (sunitinib). After initial stabilization, bone metastasis progressed during the third cycle of sunitinib and required second-line therapy (cabozantinib). One of the major unmet needs in non-clear cell RCC is the lack of specific systemic therapy. Data on immunotherapy are still limited. Inclusion of these patients in clinical trials is strongly recommended. PATIENT SUMMARY: Patients with metastatic kidney cancer who present with the less common histological subtype (non-clear cell) have poor survival. In this case, the patient responded to second-line therapy. Very few therapies provide response to treatment. Patients should be offered participation in clinical trials testing combinations with immunotherapy.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Mir MC, Albiges L, Bex A, et al. Management of Metastatic Nonclear Renal Cell Carcinoma: What Are the Options and Challenges? Eur Urol Oncol. 2020. PMID: 32553707. doi:10.1016/j.euo.2020.05.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。